



## State-of-the-Art Immunology and Immunotherapy in USA

Guest Editor:

**Prof. Dr. David T. Harris**

Department of Immunobiology &  
Medicine, College of Medicine-  
Tucson, University of Arizona  
Health Sciences, University of  
Arizona, Tucson, AZ 85724, USA

Deadline for manuscript  
submissions:

**closed (31 July 2022)**

### Message from the Guest Editor

Dear Colleagues,

Immunotherapy has become a hot topic in recent years due to its success in treating b-cell hematopoietic cancers (e.g., keytruda and car-t). However, not all blood cancers have been successfully amenable and solid tumors are still problematic. This Special Issue is concerned with applications of immunotherapy to not only novel b-cell cancers (e.g., hodgkins and NHL in addition to typical leukemias), but to other hematologic malignancies (e.g., t-cell leukemias, myeloid cancers and multiple myelomas) as well. In addition, applications of immunotherapy to the treatment of solid tumors would be welcome. Finally, the use of immunotherapy to address unmet needs in the area of autoimmune diseases is encouraged.

Prof. Dr. David Harris

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)